Clinical Trials Logo

Carcinoma, Hepatocellular clinical trials

View clinical trials related to Carcinoma, Hepatocellular.

Filter by:

NCT ID: NCT04981665 Recruiting - Clinical trials for Hepatocellular Carcinoma

A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Start date: November 8, 2021
Phase: Phase 2
Study type: Interventional

This is an open label, multi-center, phaseâ…¡study to evaluate the efficacy and safety of TACE sequential tislelizumab as adjuvant therapy in hepatocellular carcinoma (HCC) patients who are at high risk of recurrence after curative resection.

NCT ID: NCT04976634 Recruiting - Clinical trials for Colorectal Neoplasms

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

Start date: August 18, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometrial cancer (EC),and esophageal squamous cell carcinoma (ESCC). There is no formal hypothesis testing in this study.

NCT ID: NCT04975932 Completed - Clinical trials for Hepatocellular Carcinoma

Efficacy and Safety of TACE in Combination With ICIs for HCC: a Real-world Study

CHANCE001
Start date: July 1, 2021
Phase:
Study type: Observational

The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) in patients with hepatocellular carcinoma (HCC) .

NCT ID: NCT04974281 Recruiting - Clinical trials for Hepatocellular Carcinoma

PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC

Start date: January 1, 2021
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to assess the difference of safety and efficacy about PD-1 Antibody and Lenvatinib Plus transcatheter arterial chemoembolization (TACE) on downstaging hepatocellular carcinoma with BCLC B/C.

NCT ID: NCT04973098 Recruiting - Clinical trials for Advanced Hepatocellular Carcinoma

Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma

Start date: August 5, 2021
Phase: Phase 1
Study type: Interventional

A Phase I Clinical Study of CT0181 cells in Patients with Advanced Hepatocellular Carcinoma

NCT ID: NCT04970212 Completed - Clinical trials for Carcinoma, Hepatocellular

Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures

Start date: September 24, 2021
Phase:
Study type: Observational

Clinical study planned to demonstrate that the BioTraceIO Lite, available post-procedure, is effective at estimating the area of tissue damage as measured on 24-hour post-procedure (T=24hrs) CECT scan and that it is safe, based on an assessment of device-related Adverse Events. Multi-center (up to 6 investigational sites) prospective single-arm clinical investigation 50 evaluable subjects total stratified by cancer type (primary hepatocellular carcinoma vs. secondary liver metastases).

NCT ID: NCT04967495 Recruiting - Clinical trials for Hepatocellular Carcinoma Non-resectable

TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT

Start date: July 9, 2021
Phase: N/A
Study type: Interventional

This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib and iodion-125 seeds brachytherapy (TACE-Len-I) compared with TACE combined with lenvatinib (TACE-Len) for hepatocellular carcinoma (HCC) with portal vein branch tumor thrombus (branch PVTT).

NCT ID: NCT04967482 Recruiting - Clinical trials for Hepatocellular Carcinoma Non-resectable

DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC

Start date: July 9, 2021
Phase: N/A
Study type: Interventional

This study is conducted to evaluate the efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) compared with conventional transarterial chemoembolization (cTACE) as the conversion therapy for unresectable large hepatocellular carcinoma (HCC).

NCT ID: NCT04966195 Completed - Clinical trials for Hepatocellular Carcinoma Non-resectable

Stereotactic Body Radiotherapy Based Treatment for Hepatocellular Carcinoma With Extensive Portal Vein Tumor Thrombosis

Start date: December 1, 2015
Phase: N/A
Study type: Interventional

Macrovascular invasion (MVI) is common in HCC, Portal vein tumor thrombus (PVTT) is the most common form of MVI in HCC, with an incidence ranging from 44 to 62.2%. About 10% to 60% of HCC patients have PVTT at the time of diagnosis. the prognosis for those with PVTT remains poor, as their median survival is only 2-4 months via supportive care. There is currently no widely-accepted consensus for the management of HCC with PVTT. According to some guidelines in Europe and America, HCC with PVTT is regarded as Stage C per Barcelona Clinic Liver Cancer (BCLC) Staging system, and sorafenib alone is recommended as the treatment of choice. This study is to analyze the safety and efficacy of radiotherapy of hepatocellular carcinoma patients with portal vein tumor thrombosis.

NCT ID: NCT04965714 Withdrawn - Clinical trials for Resectable Hepatocellular Carcinoma

Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer

Start date: April 13, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effect of nivolumab and ADI-PEG 20 before surgery in treating patients with liver cancer that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. ADI-PEG 20 may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. Giving nivolumab and ADI-PEG 20 before surgery may help control liver cancer.